biOasis had a wonderful year ..... From being awarded a significant research grant, to numerous research collaborations producing key data validation, to new global patents being issued - the highlights of 2015 have put the company in a position of strength as we move into a new realm of exciting possibilities in 2016.
Since our last company update in March, biOasis Technologies has been active in scientific development, at international conferences, and with new Technology Access agreements that are pointing towards a prosperous future.
Rob Hutchison, CEO of biOasis Technologies, is here to discuss the positive growth of the company in more detail.
biOasis Technologies Inc. and Brigham and Women’s Hospital Inc., Enter a Neuro-Oncology Research & Collaboration Agreement
- biOasis and Brigham and Women's Hospital Inc. (“BWH”), Harvard Medical School’s distinguished teaching hospital, have entered into a collaboration to pursue work in the area of neuro-oncology.
- Dr. Sean Lawler, researcher in the Department of Neurosurgery, Harvard Medical School, will lead the BWH team.
- The collaboration intends to initially focus on the advancement to clinic of the Transcend peptide carrier, MTfp, including MTfp-TZM, MTfp-siRNA and MTfp-miRNA within GBM (glioblastoma) models.
biOasis Enters Into a Collaborative Research and Joint Funding Support Agreement Entitled “Focus on Brain”
NEWS RELEASE - May 27th, 2015
biOasis today announces that it, in partnership with the National Research Council of Canada and the Université de Sherbrooke, has been awarded a collaborative research grant by the CQDM and Brain Canada. In their “Focus on Brain” call for proposals, the partners received a number of applications from companies and academic institutions. The focus of the research agreement is to identify a new generation of potential blood-brain barrier (BBB) carrier molecules.
May 12, 2015
BIOASIS TECHNOLOGIES INC. (OTCQX:BIOAF; TSX.V:BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), has announced results from its Her2+ brain tumor model with its lead therapeutic, MTfp-TZM. The company has also provided a scientific update relating to other programs.
biOasis European Patent Granted for The Use of Transcend for the Delivery of Enzymes to Treat Lysosomal Storage Disease in The Brain
- Many Lysosomal Storage Diseases (LSDs) have or develop significant Central Nervous System (CNS) involvement and although treatment in the periphery (outside the CNS) is effective and well established, because existing therapies do not cross the blood-brain barrier, CNS mediated symptoms remain untreated.
- In animal studies, biOasis’ Transcend Platform has been shown to enable LSD therapies to enter the brain and localize within the lysosomal compartments within cells, a key requirement in treating these devastating diseases.
- This European patent has been issued and has now passed through the period of “Notice of Opposition” and therefore has been fully published. This patent grant notice is from the last of the selected jurisdictions in which biOasis has sought such protection.
April 21, 2015
BIOASIS TECHNOLOGIES INC. (OTCQX:BIOAF; TSX.V:BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), announces that the European Patent for the use of Transcend to deliver enzymes to treat Lysosomal Storage Disease to the brain has now been fully issued and has cleared the “Notice of Opposition” period.
biOasis Technologies Inc (TSXV: BTI, OTCQX:BIOAF)– 70% of people diagnosed with brain cancer won’t survive because drugs can’t penetrate the brain. biOasis has technology in development to eradicate this; BTV reports on new their findings.